1440TiP Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III “PREVENT” trial of the AIO/CAOGI/ACO

Abstract

Peritoneal relapse is seen in 60-70% of tumors of diffuse type gastric cancer (gc), compared to only 20-30% of intestinal type according to Laurens`s classification. Hyperthermic IntraPEritoneal Chemoperfusion (HIPEC) is an increasingly used therapy method for patients with peritoneal metastases. The preventive use of HIPEC could represent an elegant approach for signet ring cell gc patients (pts) before macroscopic peritoneal seeding has happened, since patients with operable disease are fit and may have potential risk of microscopic involvement, thus having a theoretical chance of cure with HIPEC even without the need for cytoreduction.